• Disease
  • Type
  • Type 2
  • Type 2 Diabetes
  • Rury R Holman

    Prominent publications by Rury R Holman

    KOL Index score: 22355

    BACKGROUND: Autoantibodies to islet-cell cytoplasm (ICA) and glutamic acid decarboxylase (GADA) can occur in apparently typical, non-insulin dependent diabetes mellitus (type 2). We investigated whether the presence of either or both antibodies characterises a subtype of diabetes and provides better prediction of requirement for insulin therapy by 6 years' follow-up than clinical variables.

    METHODS: We measured ICA and GADA at diagnosis of diabetes in a representative population of 3672 ...

    Also Ranks for: Insulin Requirement |  ica gada |  type 2 diabetes |  patients antibodies |  6 years
    KOL Index score: 20446

    BACKGROUND: The effects of pharmacological blood pressure lowering at normal or high-normal blood pressure ranges in people with or without pre-existing cardiovascular disease remains uncertain. We analysed individual participant data from randomised trials to investigate the effects of blood pressure lowering treatment on the risk of major cardiovascular events by baseline levels of systolic blood pressure.

    METHODS: We did a meta-analysis of individual participant-level data from 48 ...

    Also Ranks for: Cardiovascular Disease |  blood pressure |  secondary prevention |  individual participant |  randomised trials
    KOL Index score: 17999

    BACKGROUND: The effect of the α-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolerance is unknown. We aimed to assess whether acarbose could reduce the frequency of cardiovascular events in Chinese patients with established coronary heart disease and impaired glucose tolerance, and whether the incidence of type 2 diabetes could be reduced.

    METHODS: The Acarbose Cardiovascular Evaluation (ACE) trial was a ...

    Also Ranks for: Impaired Glucose Tolerance |  coronary heart disease |  cardiovascular death |  chinese patients |  diabetes outcomes
    KOL Index score: 17728

    BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke.

    METHODS: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned ...

    Also Ranks for: Type 2 Diabetes |  cardiovascular disease |  patients placebo |  harmony outcomes |  myocardial infarction
    KOL Index score: 17408

    CONTEXT: Treatment with diet alone, insulin, sulfonylurea, or metformin is known to improve glycemia in patients with type 2 diabetes mellitus, but which treatment most frequently attains target fasting plasma glucose (FPG) concentration of less than 7.8 mmol/L (140 mg/dL) or glycosylated hemoglobin A1c (HbA1c) below 7% is unknown.

    OBJECTIVE: To assess how often each therapy can achieve the glycemic control target levels set by the American Diabetes Association.

    DESIGN: Randomized ...

    Also Ranks for: Hba1c Levels |  7 patients |  glycemic control |  2 diabetes |  9 years
    KOL Index score: 17348

    BACKGROUND: Latent autoimmune diabetes of adulthood (LADA) differs in clinical features from type 2 diabetes. Whether this difference translates into different risks of complications remains controversial. We examined the long-term risk of microvascular complications in people enrolled in the UK Prospective Diabetes Study (UKPDS), according to their diabetes autoimmunity status.

    METHODS: We did a post-hoc analysis of 30-year follow-up data from UKPDS (UKPDS 86). UKPDS participants with ...

    Also Ranks for: Type 2 Diabetes |  latent autoimmune |  microvascular complications |  year follow |  risk composite
    KOL Index score: 17031

    BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known.

    METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy ...

    Also Ranks for: Rosiglitazone Metformin |  glycemic durability |  monotherapy failure |  plasma glucose |  ldl diabetes mellitus
    KOL Index score: 16262

    BACKGROUND: It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance.

    METHODS: In this double-blind, randomized clinical trial with a 2-by-2 factorial design, we assigned 9306 patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition ...

    Also Ranks for: Cardiovascular Events |  incidence diabetes |  hazard ratio |  valsartan placebo |  impaired glucose tolerance
    KOL Index score: 15333

    IMPORTANCE: Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor (DPP4i) use might increase heart failure (HF) risk in type 2 diabetes mellitus (T2DM). The DPP4i sitagliptin has been shown to be noninferior to placebo with regard to primary and secondary composite atherosclerotic cardiovascular (CV) outcomes in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS).

    OBJECTIVE: To assess the association of sitagliptin use with hospitalization for HF ...

    Also Ranks for: Secondary Analysis |  hhf death |  sitagliptin placebo |  heart failure |  diabetes mellitus
    KOL Index score: 15278

    OBJECTIVE: To determine the relation between systolic blood pressure over time and the risk of macrovascular or microvascular complications in patients with type 2 diabetes.

    DESIGN: Prospective observational study.

    SETTING: 23 hospital based clinics in England, Scotland, and Northern Ireland.

    PARTICIPANTS: 4801 white, Asian Indian, and Afro-Caribbean UKPDS patients, whether randomised or not to treatment, were included in analyses of incidence; of these, 3642 were included in analyses of ...

    Also Ranks for: Systolic Blood Pressure |  prospective observational study |  type 2 diabetes |  risk complications |  myocardial infarction
    KOL Index score: 14778

    Aims/hypothesis. To determine risk factors related to the incidence and progression of diabetic retinopathy over 6 years from diagnosis of Type II (non-insulin-dependent) diabetes mellitus. Methods. This report describes 1919 patients from within the United Kingdom Prospective Diabetes Study (UKPDS), with retinal photographs taken at diagnosis and 6 years later and with complete data available. Photographs were centrally graded for lesions of diabetic retinopathy using the modified Early ...

    Also Ranks for: 6 Years |  retinopathy diagnosis |  incidence progression |  type diabetes |  factors blood
    KOL Index score: 14546

    OBJECTIVE: Impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) are risk factors for diabetes, cardiovascular disease (CVD), and kidney disease. We determined the effects of ramipril and rosiglitazone on combined and individual CVD and renal outcomes in people with IGT and/or IFG in the Diabetes REduction Assessment With ramipril and rosiglitazone Medication (DREAM) trial.

    RESEARCH DESIGN AND METHODS: A total of 5,269 people aged >or=30 years, with IGT and/or IFG ...

    Also Ranks for: Renal Outcomes |  impaired glucose tolerance |  fasting glucose |  ramipril rosiglitazone |  ifg igt
    KOL Index score: 14184

    BACKGROUND: No clinical trials have assessed the effects or cost-effectiveness of sequential screening strategies to detect new cases of type 2 diabetes. We used a mathematical model to estimate the cost-effectiveness of several screening strategies.

    METHODS: We used person-specific data from a representative sample of the US population to create a simulated population of 325,000 people aged 30 years without diabetes. We used the Archimedes model to compare eight simulated screening ...

    Also Ranks for: Type 2 Diabetes |  screening strategies |  1000 people |  effectiveness analysis |  30 years
    KOL Index score: 14153

    BACKGROUND: The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown.

    METHODS: In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to ...

    Also Ranks for: Cardiovascular Events |  hazard ratio |  risk diabetes |  impaired glucose tolerance |  valine valsartan
    KOL Index score: 14041

    Patients with impaired glucose tolerance (IGT) have increased risk for developing type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Lifestyle modification and medication can prevent or delay progression to diabetes (PD), but whether such interventions also reduce the risk of CVD has not been rigorously tested. The Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial is a multinational, randomized, double-blind, 2 x 2 factorial trial ...

    Also Ranks for: Cardiovascular Disease |  impaired glucose tolerance |  nateglinide valsartan |  risk t2dm |  navigator trial


    Rury R Holman: Influence Statistics

    Sample of concepts for which Rury R Holman is among the top experts in the world.
    Concept World rank
    evaluating cardiovascular #1
    30 diabetic #1
    precision collection #1
    lowglucose events #1
    basal biphasic #1
    screen people #1
    6 years diagnosis #1
    14752 #1
    unistep bottle #1
    administered ogtts #1
    requisite data #1
    acm exscel #1
    insulin treatment satisfaction #1
    outcomes ukpds #1
    56 mmol l1 #1
    severe hypoglycemic events #1
    cprd godarts #1
    clinicaltrialsgov nct01144338 #1
    subjects reinforced advice #1
    basal normoglycemia chlorpropamide #1
    fasting normoglycaemia #1
    metformin total glp1 #1
    angiopathies follow #1
    hba1c levels proportion #1
    dapagliflozin placebo arm #1
    effects eqw #1
    insights exscel #1
    ukpdsom clinical outcomes #1
    biphasic groups iqr #1
    evaluation ace #1
    ukpds findings #1
    ee90 #1
    onceweekly exenatide #1
    cgm22 #1
    guar placebo therapy #1
    model ukpds #1
    patients intensive policy #1
    mf monotherapy #1
    degrees selectin #1
    ukpds diabetes #1
    atorvastatin fatty acids #1
    intensive policy insulin #1
    dpp4i sitagliptin #1
    retinopathy tight #1
    pound heart failure #1
    monotherapy 9 years #1
    time glycemia #1
    blood glucose instruction #1
    impact acarbose #1
    event year blindness #1

    Key People For Type 2 Diabetes

    Top KOLs in the world
    David Richard Matthews
    type 2 diabetes sri lanka growth hormone
    Frank B Hu
    type 2 diabetes cardiovascular disease physical activity
    Rury R Holman
    type 2 diabetes cardiovascular disease impaired glucose tolerance
    David Matthew Nathan
    type 2 diabetes insulin resistance cardiovascular disease
    John B Buse
    type 2 diabetes insulin degludec cardiovascular outcomes
    Tuomilehto Tuomilehto
    type 2 diabetes blood pressure north karelia

    Rury R Holman:Expert Impact

    Concepts for whichRury R Holmanhas direct influence:Type 2 diabetes,  2 diabetes,  Type 2,  Cardiovascular disease,  Diabetes mellitus,  Impaired glucose tolerance,  Heart failure,  Physical activity.

    Rury R Holman:KOL impact

    Concepts related to the work of other authors for whichfor which Rury R Holman has influence:Type 2 diabetes,  Glycemic control,  Cardiovascular disease,  Diabetic retinopathy,  Insulin resistance,  Heart failure,  Blood glucose.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    University of Oxford, Radcliffe Department of Medicine, Oxford, United Kingdom | Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK. | Diabetes Trials Unit, Radcliffe Department of Medicine, University of